Clinical Trials Sponsored by Serentis Ltd

Total 17177 results

Serentis Ltd.

Completed

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Pruritus, Atopic Dermatitis

United States
Serentis Ltd.

Completed

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

Atopic Dermatitis

Germany, Bulgaria, Finland
Regentis Biomaterials

Active, not recruiting

Pivotal Study to Evaluate the Safety and Efficacy of GelrinC for Treatment of Cartilage Defects (SAGE)

Articular Cartilage Defects in the Knee Joint

United States
Regentis Biomaterials

Unknown

Study to Evaluate the Safety and Performance of Treatment of Articular Cartilage Lesions Located on the Femoral Condyle With gelrinC

Cartilage Lesion to the Femoral Condyle
Sylentis, S.A.

Completed

SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

Ocular Hypertension | Glaucoma

Spain
Sylentis, S.A.

Completed

Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

Ocular Hypertension | Glaucoma

Spain
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
Sylentis, S.A.

Completed

Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma

Ocular Hypertension | Open Angle Glaucoma

Spain, Germany, Estonia
Sylentis, S.A.

Completed

Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Dry Eye | Ocular Pain

Spain
Sylentis, S.A.

Recruiting

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Czechia, Slovakia, Poland
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
Sylentis, S.A.

Completed

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

Choroidal Neovascularization | Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers

Spain
Sylentis, S.A.

Completed

SYL040012, Treatment for Open Angle Glaucoma (SYLTAG)

Ocular Hypertension | Open Angle Glaucoma

Spain, Germany, United States, Estonia
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Sylentis, S.A.

Completed

Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

Ocular Pain | Dry Eye Syndrome

Spain, Estonia
Sylentis, S.A.

Completed

Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Ocular Pain | Dry Eye Syndrome

Spain
Herantis Pharma Plc.

Active, not recruiting

Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE) (AdeLE)

Secondary Lymphedema

Finland, Sweden
Herantis Pharma Plc.

Terminated

A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

Secondary Lymphedema

Finland
Serenity Pharmaceuticals, Inc.

Completed

Treatment of Patients With Nocturia

Nocturia

United States
Serenity Medical, Inc.

Active, not recruiting

Venous Sinus Stenting With the River Stent in IIH

Idiopathic Intracranial Hypertension

United States
Serenity Pharmaceuticals, Inc.

Completed

Treatment of Patients With Nocturia (Non-PK Study)

Nocturia

United States
Serenity Pharmaceuticals, Inc.

Completed

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

Nocturia

United States
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
Serenity Pharmaceuticals, Inc.

Completed

Long Term Safety Assessment of SER120 in Patients With Nocturia

Nocturia

United States
Serenity Pharmaceuticals, Inc.

Completed

Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia

Nocturia

United States
Serenity Pharmaceuticals, Inc.

Completed

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 (DB4)

Nocturia

United States
Renishaw
Herantis Pharma Plc.

Active, not recruiting

Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Finland, Sweden
Cerenis Therapeutics, SA

Terminated

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (TANGO)

Familial Hypoalphalipoproteinemia

France, United States, Belgium, Canada, Israel, Italy, Netherlands
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, Netherlands, United Kingdom
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial (CHI SQUARE)

Acute Coronary Syndrome

Canada, United States, France, Netherlands
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
Herantis Pharma Plc.
Renishaw plc.

Completed

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neuro-Degenerative Disease

Sweden, Finland
Herantis Pharma Plc.
Renishaw plc.

Completed

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease

Brain Diseases | Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases

Sweden, Finland
UnionDerm
Skin of Color Society; Solta Medical; Scientis

Recruiting

Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

Melasma

United States
Chang Gung Memorial Hospital
Scientis Pharma SA

Recruiting

Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation

Hyperpigmentation; Postinflammatory

Taiwan
Dr Jean Yannis PERENTES

Recruiting

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Mesothelioma, Malignant | Carcinoma Breast Stage IV

Switzerland
Herantis Pharma Plc.
Clinical Research Services Turku - CRST Oy

Completed

Single Ascending Doses of HER-096 in Healthy Subjects

Parkinson Disease

Finland
Cerenis Therapeutics, SA
South Australian Health and Medical Research Institute

Completed

CER-001 Atherosclerosis Regression ACS Trial (CARAT)

Acute Coronary Syndromes

United States, Australia, Netherlands, Hungary
Johns Hopkins Bloomberg School of Public Health
SHARPZ (Serenity Harm Reduction Programme Zambia)

Completed

Randomized Controlled Trial of Ways to Improve OVC HIV Prevention and Well-being

Risk Behavior | Mental Health Impairment

Zambia
Johns Hopkins Bloomberg School of Public Health
SHARPZ (Serenity Harm Reduction Programme Zambia)

Completed

Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia

Alcoholism | Child Abuse | Mental Health Impairment | Domestic Violence

Zambia
Salus Ltd.
TheraVitae Ltd.

Completed

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

Critical Limb Ischemia

Hungary
Mirka Ltd
Clinius Ltd

Completed

A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin

Keratosis, Actinic | Hyperkeratotic Callus | Actinic Lesion | Solar Keratosis/Sunburn | Hyperkeratosis | Hyperkeratotic; Lesion | Hyperkeratotic Actinic Keratosis

Finland
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Paion UK Ltd.
Chiltern International Ltd.; HFL Ltd.

Completed

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

Postoperative Pain

France, Germany, Netherlands, Poland, United Kingdom, Czechia
Calcivis Ltd
Medsource UK Ltd.

Completed

Caries Lesion Activity in Orthodontic Patients - Calcivis System

Dental Caries

United Kingdom
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Xention Ltd
Ario Pharma Ltd

Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

Chronic Idiopathic Cough

United Kingdom, Ireland
Cardiovalve Ltd.
Meditrial Europe Ltd.

Recruiting

Cardiovalve Transfemoral System - FIM Study

Mitral Regurgitation

Lithuania
Vensica Therapeutics Ltd.
Blueclinical, Ltd.

Completed

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects (XAVIER)

Overactive Bladder

Portugal
Nanomedic Technologies Ltd.

Completed

Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns (SPINCARE2)

Partial Thickness Burn

Israel

Clinical Trials Sponsored by Serentis Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations